Business Description
Lucid Diagnostics Inc
NAICS : 325413
SIC : 3845
ISIN : US54948X1090
Total Employee Number:
82Description
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.34 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 2.28 | |||||
Debt-to-EBITDA | -0.49 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -11.58 | |||||
Beneish M-Score | -0.89 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 66.3 | |||||
3-Year EBITDA Growth Rate | 28 | |||||
3-Year EPS without NRI Growth Rate | 34.8 | |||||
3-Year FCF Growth Rate | 18.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 36.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 83.79 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 18.83 | |||||
9-Day RSI | 30.82 | |||||
14-Day RSI | 37.77 | |||||
3-1 Month Momentum % | 0.94 | |||||
6-1 Month Momentum % | -30.92 | |||||
12-1 Month Momentum % | -21.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.33 | |||||
Quick Ratio | 1.31 | |||||
Cash Ratio | 1.21 | |||||
Days Inventory | 25.3 | |||||
Days Sales Outstanding | 44.82 | |||||
Days Payable | 47.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -47.9 | |||||
Shareholder Yield % | -29.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -21.71 | |||||
Operating Margin % | -930.85 | |||||
Net Margin % | -959.76 | |||||
EBITDA Margin % | -943.36 | |||||
FCF Margin % | -866.56 | |||||
OCF Margin % | -860.77 | |||||
ROE % | -438.71 | |||||
ROA % | -127.25 | |||||
ROIC % | -177.22 | |||||
3-Year ROIIC % | 33.2 | |||||
ROC (Joel Greenblatt) % | -1905.49 | |||||
ROCE % | -406.71 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 21.76 | |||||
PB Ratio | 14.15 | |||||
Price-to-Tangible-Book | 14.15 | |||||
EV-to-EBIT | -2.94 | |||||
EV-to-Forward-EBIT | -3.22 | |||||
EV-to-EBITDA | -2.99 | |||||
EV-to-Forward-EBITDA | -4.01 | |||||
EV-to-Revenue | 28.21 | |||||
EV-to-Forward-Revenue | 11.31 | |||||
EV-to-FCF | -3.26 | |||||
Price-to-GF-Value | 1.17 | |||||
| Price-to-Net-Current-Asset-Value | 17.01 | |||||
| Price-to-Net-Cash | 28.35 | |||||
Earnings Yield (Greenblatt) % | -34.01 | |||||
FCF Yield % | -29.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LUCD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lucid Diagnostics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5.445 | ||
| EPS (TTM) ($) | -0.45 | ||
| Beta | 0.1539 | ||
| 3-Year Sharpe Ratio | -0.04 | ||
| 3-Year Sortino Ratio | -0.06 | ||
| Volatility % | 51.49 | ||
| 14-Day RSI | 37.77 | ||
| 14-Day ATR ($) | 0.047983 | ||
| 20-Day SMA ($) | 0.973215 | ||
| 12-1 Month Momentum % | -21.05 | ||
| 52-Week Range ($) | 0.8413 - 1.6293 | ||
| Shares Outstanding (Mil) | 190.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lucid Diagnostics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lucid Diagnostics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 08:30 | In 65 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 64 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 08:30 | 0.98 (+0.65%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 0.98 (+0.65%) | ||
| Canaccord Genuity 46th Annual Growth Conference | 2026-08-11 11:30 | 0.96 (+0.11%) | ||
| General meeting for 2026 | 2026-06-24 11:00 | 1.03 (+0.49%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 08:30 | 1.02 (-0.97%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 1.02 (-0.97%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-16 10:15 | 1.41 (+5.22%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 08:30 | 1.19 (-2.46%) |
Show
Entries
Lucid Diagnostics Inc Frequently Asked Questions
What is Lucid Diagnostics Inc(LUCD)'s stock price today?
The current price of LUCD is $0.85. The 52 week high of LUCD is $1.63 and 52 week low is $0.84.
When is next earnings date of Lucid Diagnostics Inc(LUCD)?
The next earnings date of Lucid Diagnostics Inc(LUCD) is 2026-11-12 Est..
Does Lucid Diagnostics Inc(LUCD) pay dividends? If so, how much?
Lucid Diagnostics Inc(LUCD) does not pay dividend.
Guru Commentaries on NAS:LUCD
Minot Light Capital Partners
Bullish
2025 Q3
What the manager wrote
Lucid Diagnostics markets an FDA-approved DNA test for early detection of esophageal precancer and cancer, known as EsoGuard. We believe EsoGuard has a multi-billion dollar market opportunity due to its unique capabilities and strong clinical data. The test's patient need is significant, and its clinical utility has been positively validated by independent experts. We are optimistic about the potential for Medicare reimbursement, which could lead to broader commercial adoption and meaningful revenues for Lucid. Despite concerns about dilution and corporate structure, we see substantial upside in the stock given the underappreciation of EsoGuard's value by the market.
Press Release
Articles on Lucid Diagnostics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers